Vishwanath R. Lingappa, MD, PhD
Chief Executive Officer, Chief Technology Officer, and Member of the Board of Directors
Vishwanath R. Lingappa is the Founder, Chief Technology Officer, and Co-CEO of Prosetta Biosciences, Inc, in San Francisco. Since founding the company in 2003, he is responsible for bringing in over $35M through non-dilutive government contracts, while advancing several discovery programs into multi-year licensing and commercial development agreements with pharmaceutical companies such as Bristol-Myers Squibb, AstraZeneca, and Takeda. Dr. Lingappa oversees all research and discovery efforts and has expanded Prosetta’s core technology beyond infectious disease, to oncology, central nervous system diseases, and all therapeutic areas investigated by the company to-date. Dr. Lingappa received a B.A. degree from Swarthmore College in 1975, a Ph.D. degree from The Rockefeller University, and an M.D. degree from Cornell University Medical College. He completed residency training in Internal Medicine before joining the faculty in the Departments of Physiology and Medicine at the University of California, San Francisco (UCSF) in 1982, where he ran an NIH-funded basic research laboratory for over 20 years. It was during this time that the foundational discoveries on which Prosetta’s science is based were made. He has co-authored over 90 publications. He maintains voluntary positions as Senior Scientist at the Research Institute of California Pacific Medical Center and Emeritus Professor of Physiology at UCSF. He is recipient of a Kaiser Award for excellence in teaching (1990) and is a Fellow of the American Association for the Advancement of Science (2004).
Chief Financial Officer and Assistant Corporate Secretary
William Swinerton, Chief Financial Officer and Assistant Corporate Secretary, joined what was then Prosetta Corporation in August 2006 and has held a number of accounting and finance roles including controller and Finance Director. He is responsible for directing Prosetta’s financial strategy, as well as the accounting, budgeting, and financial analysis functions. Prior to joining Prosetta, Mr. Swinerton ran the back office of a hotel in New Orleans and operated his own freelance photography business. Mr. Swinerton earned a B.A. in History from Whitman College where he graduated with distinction in his major. He also earned a Certificate in Public Accountancy and a Master of Business Administration from San Francisco State University.
Vice President of Lab Operations and Director of Investor Relations
Christine Nichols joined Prosetta in 2008 and currently serves as Vice President of Lab Operations and Director of Investor Relations. With over 10 years of experience in biotech, Mrs. Nichols has applied her broad skillset to bolster program management, facility management, and investor relations functions within the company, playing a key role in bringing in strategic pharmaceutical partnerships and private equity. Prior to Prosetta, she worked as a Research Associate at Pfizer and Elan Pharmaceuticals. Mrs. Nichols holds a Project Management Professional Certificate, and she continues to take business courses through UC Berkeley Extension. Mrs. Nichols graduated with a BS in molecular biology from the University of California San Diego.
Jeff R. Swarz, PhD
Interim Vice President of Business Development
Dr. Swarz brings 28 years of experience in product development and marketing, equity analysis, capital raising, and investment analysis for companies in various segments of the healthcare industry. He is Managing Director and Partner at MM Dillon & Co.Dr. Swarz was a Managing Director at FBR and Life Sciences Group where he was responsible for corporate finance, mergers and acquisitions and private financing. Before that, he was a partner at EGS Healthcare Capital Partners, a healthcare private equity fund investing in biotechnology, specialty pharmaceuticals, and medical device companies. As an equity analyst in biotechnology research at Credit Suisse First Boston and Goldman Sachs, Dr. Swarz was rated among Wall Street's top ten analysts in biotechnology by Institutional Investor Magazine for ten years. Dr. Swarz was a National Institutes of Health Research Fellow in Neurovirology, completed a Postdoctoral Fellowship from Johns Hopkins School of Medicine's Department of Neurology and earned a Ph.D. in Neuroscience from the University of Rochester.